Top

18-08-2017 | Screening | Article

White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)

Journal: Breast Cancer Research

Authors: Susan R. Sturgeon, J. Richard Pilsner, Kathleen F. Arcaro, Kaoru Ikuma, Haotian Wu, Soon-Mi Kim, Nayha Chopra-Tandon, Adam R. Karpf, Regina G. Ziegler, Catherine Schairer, Raji Balasubramanian, David A. Reckhow

Publisher: BioMed Central

Abstract

Background

Several studies have suggested that global DNA methylation in circulating white blood cells (WBC) is associated with breast cancer risk.

Methods

To address conflicting results and concerns that the findings for WBC DNA methylation in some prior studies may reflect disease effects, we evaluated the relationship between global levels of WBC DNA methylation in white blood cells and breast cancer risk in a case-control study nested within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) cohort. A total of 428 invasive breast cancer cases and 419 controls, frequency matched on age at entry (55–59, 60–64, 65–69, ≥70 years), year of entry (on/before September 30, 1997, on/after October 1, 1997) and period of DNA extraction (previously extracted, newly extracted) were included. The ratio of 5-methyl-2’ deoxycytidine [5-mdC] to 2’-deoxyguanine [dG], assuming [dG] = [5-mdC] + [2’-deoxycytidine [dC]] (%5-mdC), was determined by liquid chromatography-electrospray ionization-tandem mass spectrometry, an especially accurate method for assessing total genomic DNA methylation.

Results

Odds ratio (OR) estimates and 95% confidence intervals (CI) for breast cancer risk adjusted for age at entry, year of entry, and period of DNA extraction, were 1.0 (referent), 0.89 (95% CI, 0.6–1.3), 0.88 (95% CI, 0.6–1.3), and 0.84 (95% CI, 0.6–1.2) for women in the highest compared to lowest quartile levels of %5md-C (p for trend = .39). Effects did not meaningfully vary by time elapsed from WBC collection to diagnosis.

Discussion

These results do not support the hypothesis that global DNA hypomethylation in WBC DNA is associated with increased breast cancer risk prior to the appearance of clinical disease.

Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–59. doi:10.1056/NEJMra072067.CrossRefPubMed

Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983;11:6883–94.CrossRefPubMedPubMedCentral

Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77:504–10. doi:10.1021/ac0489420.CrossRefPubMed

Bestor TH. The host defence function of genomic methylation patterns. Novartis Found Symp. 1998;214:187–95. discussion 195-9, 228-32.PubMed

Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004;32:e38. doi:10.1093/nar/gnh032.CrossRefPubMedPubMedCentral

Karimi M, Johansson S, Ekstrom TJ. Using LUMA: a luminometric-based assay for global DNA-methylation. Epigenetics. 2006;1:45–8.PubMed

van Veldhoven K, Polidoro S, Baglietto L, Severi G, Sacerdote C, Panico S, Mattiello A, Palli D, Masala G, Krogh V, et al. Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015;7:67. doi:10.1186/s13148-015-0104-2. eCollection 2015.CrossRefPubMedPubMedCentral

Severi G, Southey MC, English DR, Jung CH, Lonie A, McLean C, Tsimiklis H, Hopper JL, Giles GG, Baglietto L. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat. 2014;148:665–73. doi:10.1007/s10549-014-3209-y.CrossRefPubMed

Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86. doi:10.1186/1471-2105-13-86.CrossRefPubMedPubMedCentral

10.

Garcia-Closas M, Gail MH, Kelsey KT, Ziegler RG. Searching for blood DNA methylation markers of breast cancer risk and early detection. J Natl Cancer Inst. 2013;105:678–80. doi:10.1093/jnci/djt090.CrossRefPubMedPubMedCentral

11.

Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, Karpf AR. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis. 2009. doi:10.1093/carcin/bgp143. PMID: 1958413

12.

Deroo LA, Bolick SC, Xu Z, Umbach DM, Shore D, Weinberg CR, Sandler DP, Taylor JA. Global DNA methylation and one-carbon metabolism gene polymorphisms and the risk of breast cancer in the sister study. Carcinogenesis. 2014;35:333–8. doi:10.1093/carcin/bgt342.CrossRefPubMed

13.

Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H, KConFab Investigators, Riboli E, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res. 2012;72:2304–13. doi:10.1158/0008-5472.CAN-11-3157.CrossRefPubMed

14.

Wu HC, Delgado-Cruzata L, Flom JD, Perrin M, Liao Y, Ferris J, Santella RM, Terry MB. Repetitive element DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the BCFR. Carcinogenesis. 2012. doi:10.1093/carcin/bgs201.

15.

Xu X, Gammon MD, Hernandez-Vargas H, Herceg Z, Wetmur JG, Teitelbaum SL, Bradshaw PT, Neugut AI, Santella RM, Chen J. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J. 2012;26:2657–66. doi:10.1096/fj.11-197251.CrossRefPubMedPubMedCentral

16.

Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, Dalay N, Santella RM. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res. 2010;30:2489–96.PubMedPubMedCentral

17.

Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Dos Santos Silva I, Peto J, Boshoff C, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet. 2009;18:1332–42. doi:10.1093/hmg/ddp033.CrossRefPubMedPubMedCentral

18.

Kitkumthorn N, Tuangsintanakul T, Rattanatanyong P, Tiwawech D, Mutirangura A. LINE-1 methylation in the peripheral blood mononuclear cells of cancer patients. Clin Chim Acta. 2012;413:869–74. doi:10.1016/j.cca.2012.01.024.CrossRefPubMed

19.

Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One. 2008;3:e2656. doi:10.1371/journal.pone.0002656.CrossRefPubMedPubMedCentral

20.

Delgado-Cruzata L, Wu HC, Perrin M, Liao Y, Kappil MA, Ferris JS, Flom JD, Yazici H, Santella RM, Terry MB. Global DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the breast cancer family registry. Epigenetics. 2012;7:868-74. doi:10.4161/epi.20830. Epub 2012 Jun 18.

21.

Kuchiba A, Iwasaki M, Ono H, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Tsugane S, Yoshida T. Global methylation levels in peripheral blood leukocyte DNA by LUMA and breast cancer: a case-control study in Japanese women. Br J Cancer. 2014;110:2765–71. doi:10.1038/bjc.2014.223.CrossRefPubMedPubMedCentral

22.

Brennan K, Flanagan JM. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res (Phila). 2012;5:1345–57. doi:10.1158/1940-6207.CAPR-12-0316.CrossRef

23.

Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005;592:147–54. PMID: 16054167.

24.

Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–4. PMID: 17529973.

25.

Lacey Jr JV, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, Hoover RN, Prorok PC, Berg CD, Hartge P, et al. Breast cancer epidemiology according to recognized breast cancer risk factors in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial cohort. BMC Cancer. 2009;9:84. doi:10.1186/1471-2407-9-84.CrossRefPubMedPubMedCentral

26.

Dugue PA, English DR, MacInnis RJ, Jung CH, Bassett JK, FitzGerald LM, Wong EM, Joo JE, Hopper JL, Southey MC, et al. Reliability of DNA methylation measures from dried blood spots and mononuclear cells using the HumanMethylation450k BeadArray. Sci Rep. 2016;6:30317. doi:10.1038/srep30317.

27.

Tang Q, Cheng J, Cao X, Surowy H, Burwinkel B. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.Clin Epigenetics. 2016;8:115. doi:10.1186/s13148-016-0282-6.

28.

Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet. 2014;30:75–84. doi:10.1016/j.tig.2013.11.004.

29.

Wu HC, Delgado-Cruzata L, Flom JD, Kappil M, Ferris JS, Liao Y, Santella RM, Terry MB. Global methylation profiles in DNA from different blood cell types. Epigenetics. 2011;6. doi:10.4161/epi.6.1.13391.

30.

Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics. 2011;6:828-37. doi:10.4161/epi.6.7.16500. Epub 2011 July 1.

31.

Xu Z, Bolick SC, Deroo LA, Weinberg CR, Sandler DP, Taylor JA. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J Natl Cancer Inst. 2013;105:694–700. doi:10.1093/jnci/djt045.CrossRefPubMedPubMedCentral